tumor antigen dependent manner. We are now evaluating these noval constructs for their ability to induce phagocytosis in different APCs. In addition we are looking into the effects these antibodies have on cytokine expression and expression of other immune regulatory markers. In-vivo we are using SPECT/CT and biodistribution analysis to determine their tumor targeting ability. Ultimately, we would like to show whether tumor targeted inhibition of the CD47-SIRPa axis using the bifunctional antibodies results in improved anti-tumor immunity

Disclosure Information F. Schuurmans: None. **A. Wittner:** None. **R.J.E. van den Bijgaart:** None. **S. Tahk:** None. **S. Heskamp:** None. **K. Hopfner:** None. **G.J. Adema:** None.

Poster Presentations

P01 Emerging concepts/new agents

P01.01 PLAP AS TARGET FOR CANCER IMMUNOTHERAPY – DEVELOPMENT AND PRECLINICAL CHARACTERIZATION OF BISPECIFIC MONOCLONAL ANTIBODY IN COLORECTAL CANCER IMMUNOTHERAPY

[1]NS Alrishedan*, [1]W Bodmer, [1]V Liebe lastun, [2]V Golubovskaya, [2]J Wu, [3]A Bransi, [3]P Umana, [3]C Klein, [3]R Mateus Seidl. *[1]Weatherall Institute of Molecular Medicine, Oxford University, Oxford, UK; [2]ProMab Biotechnologies, California USA, CA, USA; [3]Roche Glycart AG, Switzerland, Switzerland*

10.1136/jitc-2022-ITOC9.13

Immunotherapy using T cell-engaging bispecific monoclonal antibodies (BiMAb) is a promising cancer therapy. Such BiMAbs bind simultaneously to immune effector cells and to a cancer-specific antigen on tumor cells, resulting in killing of the latter. Placental alkaline phosphatase (PLAP), a plasma membrane-bound glycoprotein, is one of the four members of alkaline phosphatase isozyme family. PLAP is encoded by the *ALPP* gene. PLAP is expressed in placenta and has not been detected in other normal tissues. It has been shown that PLAP is released into the serum of patients with PLAP expressing tumours such as testis tumours. When PLAP is expressed ectopically in cancers, such as ovarian or colon carcinomas, it is essentially cancer specific and so an excellent target for immune based antibody therapy .The focus of my work is on colorectal cancer (CRC) and will mainly be based on the use of a well characterised panel of over 100 colorectal cancer derived cell lines about 20% of which express PLAP at the mRNA and protein levels . The cell lines are good representatives of primary tumors to use for in vitro preclinical testing of a new immunotherapeutic PLAP x CD3 BiMAb being developed for treatment of CRC. Worldwide, colorectal cancer has one of the highest cancer incidences and in the United States is the third cause of mortality in cancer patients. This emphasises the need to find novel effective treatments for colon cancer We found that a CD3 x PLAP BiMAb induced specific killing of PLAP-positive colorectal cancer cell lines, using peripheral blood mononuclear cells (PBMCs) as source of T cells, and that the killing depends on PLAP expression. The expression of PLAP in our cells varies and there is heterogeneity of PLAP expression within cell lines. However, we found that the effect of CD3 x PLAP BiMAb treatment was extended to PLAP-negative cells, when co-cultured with PLAP-positive ones, indicating a bystander effect. The bystander effect on PLAP-negative cells is only visible after 48 hours of treatment, suggesting an indirect killing mechanism. The important to study bystander killing to target cancer cells immune killing escape.To investigate further the mechanism of bystander killing, our early findings suggest CD3 x PLAP BiMAb activated T cells induce killing on bystander killing. We are studying the effect of the T cells subtypes and of the soluble factors secreted by the activated T cells.

Disclosure Information N.S. Alrishedan: None. **W. Bodmer:** F. Consultant/Advisory Board; Modest; ProMab Biotechnologies. **V. Liebe lastun:** B. Research Grant (principal investigator, collaborator or consultant and pending grants as well as grants already received); Modest; Roche Glycart AG , Switzerland. **V. Golubovskaya:** A. Employment (full or part-time); Modest; ProMab Biotechnologies. **J. Wu:** A. Employment (full or part-time); Modest; ProMab Biotechnologies. **A. Bransi:** A. Employment (full or part-time); Modest; Roche Glycart AG, , Switzerland. **P. Umana:** A. Employment (full or part-time); Modest; Roche Glycart AG, , Switzerland. **C. Klein:** A. Employment (full or part-time); Modest; Roche Glycart AG, , Switzerland. **R. Mateus Seidl:** A. Employment (full or part-time); Modest; Roche Glycart AG, , Switzerland.

P01.02 SELECTIVE INDUCTION OF CELL DEATH IN JURKAT CELLS WITH RECOMBINANT FUNGAL LECTIN CNL

[1]MM Perisic Nanut*, [1]S Žurga, [1]Š Konjar, [1]M Prunk, [2]J Kos, [1]J Sabotič. *[1]Institute Jozef Stefan, Ljubljana, Slovenia; [2]Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia*

10.1136/jitc-2022-ITOC9.14

Background Due to their capacity to specifically recognize subtle alterations in glycoproteins on the cell surface lectins are increasingly being used in diagnostic (for identification of malignant or premalignant cells) and therapeutic purposes (for targeted drug delivery).

Materials and Methods We have previously isolated and biochemically characterized a fungal lectin Clitocybe nebularis lectin (CNL) . We have synthetized recombinant form of CNL and tested its effects on different human cell lines and primary cells using various biochemical and molecular biological assays.

Results CNL is a GalNAcβ1–4GlcNAc-binding lectin that shows an antiproliferative effect solely on the leukemic Jurkat T cells. Furthermore, recombinant CNL treated Jurkat T cells exhibited archetypal features of early apoptosis, homotypic agglutination but lacked the activation of initiating and executing caspases since none of the features of CNL-induced cell death was effectively blocked with the pan-caspase inhibitor or different peptidase inhibitors. In addition, CNL binding induced Jurkat cells to release the endogenous damage-associated molecular pattern molecule high-mobility group box 1 (HMGB1), which is typically associated with necroptosis. We have identified CD45 and CD43 cell surface glycoproteins as main binding targets on the cell surface of Jurkat cells. However, the blockade of CD45 phosphatase activity failed to block either CNL-induced homotypic agglutination or cell death. Remarkably, a plant lectin, *Wisteria floribunda* agglutinin (WFA), which shows similar specificity in ligand binding, showed less selective cytotoxicity and induced cell death in Jurkat cells, Tall-104 acute lymphoblastic leukemia, and Hut-